Novartis Ag

Chikwendu Ibebunjo

Jun Yuan

Frederic Zecri

David Weninger Barnes

Ken Yamada

Louise Clare Kirman

Aimee Richardson Usera

Eveline Schaadt

Aaron Kanter

Alexandra Marshall Bruce

Changgang Lou

Carsten Jacobi

Angelika Meyer

Anne-Ulrike Trendelenburg

Olga Vladimirovna Mitina

Donglin Guo

Alokesh Duttaroy

This invention is in the field of anti-transforming growth factor beta 2 (TGF-&#x3b2;2) antibodies. In particular, the invention provides human monoclonal antibodies that bind the human TGF-&#x3b2;2 isoform preferentially over the human TGF-&#x3b2;1 or TGF-&#x3b2;3 isoforms.

TGFbeta 2 antibodies

The present disclosure is directed to compositions and methods related to an alpha sKlotho variant or fragment, in which 1 to up to about 20 amino acids have been deleted from the C-terminus, optionally also having mutations at V563 and/or K795. The present disclosure also pertains to an alpha sKlotho polypeptide variant or fragment, having mutations at V563 and/or K795, wherein the polypeptide variant or fragment is full-length, or optionally 1 to up to about 20 amino acids have been deleted from the C-terminus. The present disclosure also pertains to fusion polypeptides comprising: (a) an alpha sKlotho, in which 1 to up to about 20 amino acids have been deleted from the C-terminus, optionally also having mutations at V563 and/or K795; (b) a linker; and (c) FGF23, optionally having a mutation at R179, C206 and/or C244, or (c) serum albumin.

Soluble alpha klotho and serum albumin fusion protein

Growing community of inventors

Newton, MA, United States of America

Chikwendu Ibebunjo